LYSOGENE The Genes for Success
Lysogene is a French biotech present in the gene therapy area. It is focused on rare genetic diseases affecting the CNS and more particularly lysosomal storage disorders. Gene therapy is an exciting new field as illustrated by the more than 300 drugs under development and the M&A deals that have been concluded for significant amounts (Novartis/AveXis for USD8.7bn or Roche/Spark Therapeutics for potentially USD4.8bn). Lysogene has developed significant know-how in this field and is the most clinically advanced gene therapy company in Europe.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.